Drug intelligence / Profile preview

RVX-002

Development stage: Preclinical
Lead developer: ReNewVax
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

RVX-002 is a preclinical-stage recombinant protein vaccine being developed by ReNewVax to prevent invasive Group B Streptococcus (GBS) disease. The vaccine targets conserved antigens of *Streptococcus agalactiae*, aiming to provide broad protection against various GBS serotypes. It is intended for the prevention of neonatal sepsis, meningitis, and pneumonia, as well as stillbirth and pre-term birth. Additionally, the vaccine is being explored for use in elderly and immunocompromised populations who are at high risk for invasive GBS infections.

Other names: RVX-002RVX002RVX 002

Targets

Conserved Streptococcus agalactiae surface protein antigens

Beyond the preview

Go deeper on RVX-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RVX-002.

Explore the full profile